Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
Year: 2019
Type: letter
Authors: Pramod K. Mistry, Manisha Balwani, Hagit N. Baris, Hadhami Ben Turkia, T. Andrew Burrow, Joel Charrow, Gerald F. Cox, Sumita Danda, Marta Dragosky, Guillermo Drelichman, Amal El-Beshlawy, Cristina Fraga, Selena Freisens, Sebastiaan Gaemers, Evgueniy Hadjiev, Priya S. Kishnani, Elena Lukina, Pierre Maison-Blanche, Ana Maria Martins, Gregory Pastores, Milan Petakov, M. Judith Peterschmitt, Hanna Rosenbaum, Barry Rosenbloom, Lisa H. Underhill, Timothy M. Cox
Institutions: Yale University, Icahn School of Medicine at Mount Sinai, Technion – Israel Institute of Technology, Rambam Health Care Campus, Hôpital La Rabta, University of Arkansas for Medical Sciences, Northwestern University, Lurie Children's Hospital, Christian Medical College, Vellore, Hospital General de Niños Ricardo Gutierrez, Cairo University, Cairo University hospitals, Hospital do Divino Espírito Santo, Alexandrovska Hospital, Duke University, National Medical Research Center for Hematology, Hôpital Bichat-Claude-Bernard, Universidade Federal de São Paulo, New York University, University of Belgrade, Univerzitetski Klinički Centar Srbije, Cedars-Sinai Medical Center, University of Cambridge, Addenbrooke's Hospital
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Pfizer, Sanofi Genzyme
OpenAlex ID: W2937063591